Giorgio Papiani

426 total citations
19 papers, 270 citations indexed

About

Giorgio Papiani is a scholar working on Surgery, Neurology and Oncology. According to data from OpenAlex, Giorgio Papiani has authored 19 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 8 papers in Neurology and 7 papers in Oncology. Recurrent topics in Giorgio Papiani's work include Testicular diseases and treatments (11 papers), Neuroblastoma Research and Treatments (8 papers) and Colorectal and Anal Carcinomas (6 papers). Giorgio Papiani is often cited by papers focused on Testicular diseases and treatments (11 papers), Neuroblastoma Research and Treatments (8 papers) and Colorectal and Anal Carcinomas (6 papers). Giorgio Papiani collaborates with scholars based in Italy, Türkiye and United States. Giorgio Papiani's co-authors include Ugo De Giorgi, Giovanni Rosti, M. Marangolo, Michela Ballardini, H. Wandt, Jody Corbelli, Christian Taverna, Martin Bornhäuser, Maria Aurelia Barbera and Elisa Grassi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Giorgio Papiani

18 papers receiving 270 citations

Peers

Giorgio Papiani
Maria Koumpou Greece
J.P. Droz France
Maria Gry Gundgaard Denmark
Wendy Ansell United Kingdom
Dalyong Kim South Korea
Matthew Boron United States
Maurizio Lalle Italy
DeQuincy Andrew Lewis United States
S. Provent France
Eva Hoff Wanderås Norway
Maria Koumpou Greece
Giorgio Papiani
Citations per year, relative to Giorgio Papiani Giorgio Papiani (= 1×) peers Maria Koumpou

Countries citing papers authored by Giorgio Papiani

Since Specialization
Citations

This map shows the geographic impact of Giorgio Papiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giorgio Papiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giorgio Papiani more than expected).

Fields of papers citing papers by Giorgio Papiani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giorgio Papiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giorgio Papiani. The network helps show where Giorgio Papiani may publish in the future.

Co-authorship network of co-authors of Giorgio Papiani

This figure shows the co-authorship network connecting the top 25 collaborators of Giorgio Papiani. A scholar is included among the top collaborators of Giorgio Papiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giorgio Papiani. Giorgio Papiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rossini, Daniele, Lisa Salvatore, Alessandro Passardi, et al.. (2024). 535P Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience. Annals of Oncology. 35. S448–S448. 1 indexed citations
2.
Zingaretti, Chiara, Giorgio Papiani, Sara Pini, et al.. (2022). A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.. Journal of Clinical Oncology. 40(17_suppl). LBA3513–LBA3513. 16 indexed citations
3.
Grassi, Elisa, et al.. (2021). Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Frontiers in Oncology. 11. 601722–601722. 34 indexed citations
4.
Tamberi, Stefano, Elisa Grassi, Jody Corbelli, et al.. (2021). A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.. Journal of Clinical Oncology. 39(15_suppl). 3607–3607. 7 indexed citations
5.
Tamberi, Stefano, Elisa Grassi, Maria Aurelia Barbera, et al.. (2020). A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer (PANDORA).. Journal of Clinical Oncology. 38(4_suppl). TPS259–TPS259. 1 indexed citations
6.
Barbera, Maria Aurelia, Jody Corbelli, Giorgio Papiani, et al.. (2019). A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study. Annals of Oncology. 30. v249–v249. 1 indexed citations
7.
Burgio, Salvatore Luca, Cecilia Menna, Giorgio Papiani, et al.. (2013). Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours. Journal of Chemotherapy. 25(2). 119–122.
8.
Dazzi, Claudio, Anna Cariello, Cláudia Casanova, et al.. (2012). Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study. Clinical Lung Cancer. 14(1). 28–33. 12 indexed citations
9.
Giorgi, Ugo De, Giovanni Rosti, Roberto Salvioni, et al.. (2009). Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. Urologic Oncology Seminars and Original Investigations. 29(3). 284–290. 12 indexed citations
10.
11.
Brames, Mary J., Giorgio Papiani, & Lawrence Einhorn. (2007). Results with salvage chemotherapy with high dose carboplatin + etoposide and peripheral blood stem cell transplant in male choriocarcinoma. Journal of Clinical Oncology. 25(18_suppl). 5091–5091. 1 indexed citations
12.
Giorgi, Ugo De, T. Demirer, H. Wandt, et al.. (2004). Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Annals of Oncology. 16(1). 146–151. 58 indexed citations
13.
Giorgi, Ugo De, Giovanni Rosti, Giorgio Papiani, & M. Marangolo. (2004). Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience. Bone Marrow Transplantation. 33(6). 639–643. 2 indexed citations
14.
Giorgi, Ugo De, Giovanni Rosti, Giorgio Papiani, et al.. (2004). Weekly Gemcitabine, Paclitaxel, Oxaliplatin Combination Chemotherapy in Patients With Cisplatin-Refractory Germ Cell Tumor. American Journal of Clinical Oncology. 27(5). 457–460. 15 indexed citations
15.
Rosti, Gianantonio, Ugo De Giorgi, H. Wandt, et al.. (2004). First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplantation. 34(12). 1033–1037. 24 indexed citations
16.
Giorgi, Ugo De, et al.. (2003). High-Dose Chemotherapy in Adult Patients with Germ Cell Tumors. Cancer Control. 10(1). 48–56. 8 indexed citations
17.
Giorgi, Ugo De, Giovanni Rosti, Giorgio Papiani, & M. Marangolo. (2002). The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.. PubMed. 87(1). 95–104. 27 indexed citations
18.
Rosti, Giovanni, Ugo De Giorgi, Roberto Salvioni, et al.. (2002). Salvage high‐dose chemotherapy in patients with germ cell tumors. Cancer. 95(2). 309–315. 23 indexed citations
19.
Fiorentini, Giammaria, S Lucchi, Petros Giovanis, et al.. (2001). Irinotecan Hepatic Arterial Infusion Chemotherapy for Hepatic Metastases from Colorectal Cancer: Results of a Phase I Clinical Study. Tumori Journal. 87(6). 388–390. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Koumpou Breakdown of academic impact, for papers by J.P. Droz Breakdown of academic impact, for papers by Maria Gry Gundgaard Breakdown of academic impact, for papers by Wendy Ansell Breakdown of academic impact, for papers by Dalyong Kim Breakdown of academic impact, for papers by Matthew Boron Breakdown of academic impact, for papers by Maurizio Lalle Breakdown of academic impact, for papers by DeQuincy Andrew Lewis Breakdown of academic impact, for papers by S. Provent Breakdown of academic impact, for papers by Eva Hoff Wanderås
Rankless by CCL
2026